We help grow young biotechnology companies
providing the capital, guidance and critical knowledge that early and mid stage companies need to succeed
We offer early and clinical stage financing accompanied by business mentoring and ‘hands-on’ involvement when needed
About Us
Altius Impact Partners is a Canadian headquartered venture capital company that invests in promising early and mid-stage companies in the field of biotechnology worldwide. It’s also a venture capital platform for family offices and private investors willing to invest in highly promising biotech companies around the globe.
Altius Impact was founded in 2009 with initial focus on advisory services in Mergers & Acquisitions. Our mission now is to invest in projects that have the potential to embody innovation, scale, and sustainability, providing for greatest possible impact in the sectors of biotechnology and life sciences.
Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.
What Makes Us Different?
Altius brings a uniquely global perspective (and connections) to investments and helping founders. Having successfully invested around the world, in diverse regions and during challenging times,enables us to provide the kind of meaningful insights that can make a real difference to a company’s success. It has also provided us with the business savvy and grit that make us trusted partners on the road to building a world class company.
Leadership
Anatole Klepatsky – CEO
Anatole Klepatskyi is an investment banking and biotech expert. Anatole is a board member of Orion Biotechnology, a biotechnology company founded in 2011 which is involved in development of innovative products in the field of oncology, neurological diseases and HIV prevention. Anatole was born in Ukraine where he started his professional career in 1994 with Credit Commercial de France (CCF) working on the implementation of the mass privatization program and various M&A transactions. Since 2000, Anatole lead a number of M&A firms in investment banking field with over 35 transactions with total value in excess of $1.7 billion successfully completed under his leadership.
Advisory Board
Perry Molinoff
Dr. Molinoff is a Professor of Pharmacology at the University of Pennsylvania with more than 30 years of experience in both the academic and industrial sectors. Previously, Dr. Molinoff served as the Vice Provost for Research of the University of Pennsylvania where he developed linkages between the University and industry to enable transfer of technologies from university laboratories for commercial application. Dr. Molinoff served as the Executive Vice President of Research and Development at Palatin Technologies, and Vice President of Neuroscience and Genitourinary Drug Discovery for the Bristol-Meyers Squibb Pharmaceutical Research Institute. He serves as a member of Advisory Board at BioMotiv, LLC and served as its serves as a member of the Scientific Advisory Board. He has served on the Board of Directors of both public and private companies including Cypress Bioscience and Palatin Technologies, and has served on multiple editorial advisory boards. Dr. Molinoff has also authored or edited more than 230 publications and six books. Dr. Molinoff earned his undergraduate and medical degrees from Harvard University.
George Tarainor
George Trainor received a B.S. degree in Chemistry from Stevens Institute of Technology in 1974. He pursued graduate studies under Prof. Yoshito Kishi at Harvard University and received M.S and Ph.D. degrees in Chemistry in 1979. Following postdoctoral studies under Prof. Ronald Breslow at Columbia University, he joined the Central Research and Development Department of the DuPont Company in 1981. After working on the chemistry of metals and carbohydrates, he initiated a project which led to the discovery and commercialization of fluorescence-tagged chain terminators for use in automated DNA sequencing. In 1991, he moved into the newly formed DuPont Merck Pharmaceutical Company working on nucleic acid-based therapeutics. After heading up the cancer therapeutic area in 1993, he moved into medicinal chemistry working in several therapeutic areas as a Senior Director under Paul Anderson. From 2002 through 2010, he worked at the Bristol-Myers Squibb Company in Lawrenceville, New Jersey as Vice President – Oncology Chemistry and Early Discovery Chemistry, leading a team of 115 chemists. His teams advanced over 30 compounds into pharmaceutical development. In 2011 he received the Heroes of Chemistry Award from the American Chemical Society for his early work of fluorescence-tagged DNA sequencing.
Paul Williamson
Dr. Paul Williamson earned his BS and MD degrees from the University of Massachusetts. He completed a medical residency at the St. Vincent Hospital in Worcester and a rheumatology fellowship at the Hospital of the University of Pennsylvania in Philadelphia. He is a board certified internist and rheumatologist. In addition to practicing rheumatology in Massachusetts, he was the Chief of Medicine at the Union Hospital Campus of the North Shore Medical Center, the Medical Director of the North Shore Medical Group, Inc., a member of the Executive Committee of Charter Professional Services Corporation, a subsidiary of Partners HealthCare System, and a member of Partners HealthCare Chiefs’ Council.
Dr. Williamson joined the Johnson & Johnson Family of Companies in 2001 and left in 2014 to individually pursue development of and investment in early stage technologies to satisfy unmet medical needs. He currently serves on the Advisory Board of the Innovation Support Center of Harrington Discovery Institute, where he advises University-based physician scientists on accelerating the development of their inventions toward commercialization. In addition, he is actively involved with Charleston Angel Partners as an investor in early stage technologies within the life sciences.
Altius brings a uniquely global perspective to investments. We are connecting great scientists, passionate entrepreneurs and value based investors together. Having successfully invested around the world, in diverse regions and during challenging times, enables us to provide the kind of meaningful insights that can make a real difference to a company’s success.
Contact Us
You may use the contact form below in order to get in touch with us for more information.